Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo de estudio
Tipo del documento
Intervalo de año de publicación
1.
Mol Pharm ; 17(10): 3649-3653, 2020 10 05.
Artículo en Inglés | MEDLINE | ID: mdl-32857512

RESUMEN

Adeno-associated virus (AAV)-based gene therapy is currently limited by (1) decline in therapeutic gene expression over time, (2) immune cell activation and (3) neutralization by pre-existing antibodies. Hence, studying the interaction of AAV vectors with various cellular pathways during the production and transduction process is necessary to overcome such barriers. Post-translational modifications (PTM) of AAV vectors during the production and transduction process is known to limit its transduction efficiency and further evoke the immune response. Further, AAV vectors are known to trigger cellular stress, resulting in an upregulation of distinct arms of the unfolded protein response (UPR) pathway. Recognition of the AAV genome by Toll-like receptor-9 triggers the myeloid differentiation primary response signaling cascade for innate (IL-6, IFN-α, IFN-ß) and adaptive (CD8+ T-cell, B-cell) immune response against the viral capsid and the transgene product. Herein, we highlight a potential intersection of the UPR, PTMs, and intracellular trafficking pathways, which could be fine-tuned to augment the outcome of AAV-based gene delivery.


Asunto(s)
Dependovirus/inmunología , Terapia Genética/métodos , Interacciones Microbiota-Huesped/inmunología , Procesamiento Proteico-Postraduccional/inmunología , Transducción Genética/métodos , Inmunidad Adaptativa/genética , Animales , Proteínas de la Cápside/genética , Proteínas de la Cápside/inmunología , Dependovirus/genética , Interacciones Microbiota-Huesped/genética , Humanos , Inmunidad Innata/genética , Procesamiento Proteico-Postraduccional/genética , Respuesta de Proteína Desplegada/genética , Respuesta de Proteína Desplegada/inmunología
2.
PLoS One ; 8(1): e53845, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23320106

RESUMEN

The unfolded protein response (UPR) is a stress-induced cyto-protective mechanism elicited towards an influx of large amount of proteins in the endoplasmic reticulum (ER). In the present study, we evaluated if AAV manipulates the UPR pathways during its infection. We first examined the role of the three major UPR axes, namely, endoribonuclease inositol-requiring enzyme-1 (IRE1α), activating transcription factor 6 (ATF6) and PKR-like ER kinase (PERK) in AAV infected cells. Total RNA from mock or AAV infected HeLa cells were used to determine the levels of 8 different ER-stress responsive transcripts from these pathways. We observed a significant up-regulation of IRE1α (up to 11 fold) and PERK (up to 8 fold) genes 12-48 hours after infection with self-complementary (sc)AAV2 but less prominent with single-stranded (ss)AAV2 vectors. Further studies demonstrated that scAAV1 and scAAV6 also induce cellular UPR in vitro, with AAV1 vectors activating the PERK pathway (3 fold) while AAV6 vectors induced a significant increase on all the three major UPR pathways [6-16 fold]. These data suggest that the type and strength of UPR activation is dependent on the viral capsid. We then examined if transient inhibition of UPR pathways by RNA interference has an effect on AAV transduction. siRNA mediated silencing of PERK and IRE1α had a modest effect on AAV2 and AAV6 mediated gene expression (∼1.5-2 fold) in vitro. Furthermore, hepatic gene transfer of scAAV2 vectors in vivo, strongly elevated IRE1α and PERK pathways (2 and 3.5 fold, respectively). However, when animals were pre-treated with a pharmacological UPR inhibitor (metformin) during scAAV2 gene transfer, the UPR signalling and its subsequent inflammatory response was attenuated concomitant to a modest 2.8 fold increase in transgene expression. Collectively, these data suggest that AAV vectors activate the cellular UPR pathways and their selective inhibition may be beneficial during AAV mediated gene transfer.


Asunto(s)
Dependovirus/genética , Respuesta de Proteína Desplegada/genética , Factor de Transcripción Activador 6/genética , Animales , Dependovirus/clasificación , Dependovirus/inmunología , Estrés del Retículo Endoplásmico/genética , Endorribonucleasas/genética , Vectores Genéticos/inmunología , Células HeLa , Humanos , Inmunidad Innata/genética , Ratones , Ratones Endogámicos BALB C , Proteínas Serina-Treonina Quinasas/genética , Transducción de Señal/genética , Transducción Genética , Respuesta de Proteína Desplegada/efectos de los fármacos , eIF-2 Quinasa/genética
3.
Mol Ther ; 18(12): 2048-56, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-20736929

RESUMEN

Elimination of specific surface-exposed single tyrosine (Y) residues substantially improves hepatic gene transfer with adeno-associated virus type 2 (AAV2) vectors. Here, combinations of mutations in the seven potentially relevant Y residues were evaluated for further augmentation of transduction efficiency. These mutant capsids packaged viral genomes to similar titers and retained infectivity. A triple-mutant (Y444+500+730F) vector consistently had the highest level of in vivo gene transfer to murine hepatocytes, approximately threefold more efficient than the best single-mutants, and ~30-80-fold higher compared with the wild-type (WT) AAV2 capsids. Improvement of gene transfer was similar for both single-stranded AAV (ssAAV) and self-complementary AAV (scAAV) vectors, indicating that these effects are independent of viral second-strand DNA synthesis. Furthermore, Y730F and triple-mutant vectors provided a long-term therapeutic and tolerogenic expression of human factor IX (hF.IX) in hemophilia B (HB) mice after administration of a vector dose that only results in subtherapeutic and transient expression with WT AAV2 encapsidated vectors. In summary, introduction of multiple tyrosine-mutations into the AAV2 capsid results in vectors that yield at least 30-fold improvement of transgene expression, thereby lowering the required therapeutic dose and potentially vector-related immunogenicity. Such vectors should be attractive for treatment of hemophilia and other genetic diseases.


Asunto(s)
Dependovirus/genética , Terapia Genética , Hemofilia B/genética , Hemofilia B/terapia , Transducción Genética , Animales , Vectores Genéticos/genética , Células HeLa , Hepatocitos/metabolismo , Humanos , Ratones , Ratones Endogámicos C57BL , Plásmidos , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Tirosina/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA